Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1354564

registered interest
date	10/09/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Regional Planning and Development: Science and Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to prioritise science and research in the levelling up agenda in (a) Newport West constituency, (b) Wales and (c) the UK.
tabling member constituency	Newport West
tabling member printed	Ruth Jones
uin	47052
answer	answer is ministerial correction date of answer 20/09/2021 answer text <p>We recognise the need to take a comprehensive place-based approach to economic growth, that responds to the varying needs of places. We will publish a detailed approach for levelling up through R&amp;D as part of the forthcoming Levelling Up White Paper.</p><p> </p><p>Ahead of then, UKRI’s Strength in Places Fund (SIPF) is the first major national competitive R&amp;D fund that takes a place-based approach contributing to the Government’s wider levelling up ambitions. In June 2020, BEIS announced an award of £25m to the CS Connected project in the first wave of SIPF, to develop South Wales’ compound semiconductor cluster. Project partners are from across the region including Newport. This summer, BEIS announced a £22m award to the media.cymru project to develop Cardiff’s media cluster.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/09/2021 15:35:22 answering member 4020 label Biography information for George Freeman
tabling member	4716 label Biography information for Ruth Jones

458112

registered interest
date	07/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many instances of adverse reactions have been reported under the Yellow Card Scheme; and what the nature of the reaction reported was in the case of (a) dabigatran, (b) rivaroxaban and (c) apixaban.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	29973
answer	answer is ministerial correction date of answer 10/03/2016 answer text <p>Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines through the spontaneous reporting scheme, the Yellow Card Scheme. The scheme collects suspected ADR reports from the whole of the United Kingdom in relation to all medicines and vaccines. Reporting to the Yellow Card Scheme is voluntary for healthcare professionals and members of the public. There is also a legal obligation for pharmaceutical companies to report all serious ADRs for their products that they are aware of.</p><p> </p><p>The table below provides the number of UK suspected spontaneous ADR reports received via the Yellow card Scheme in association with each drug substance as requested.</p><p> </p><p>The information in the table shows the number of UK spontaneous suspected ADR reports in association with Dabigatran, Rivaroxaban and Apixaban up to and including 7 March 2016.</p><table><tbody><tr><td><p>Drug substance</p></td><td><p>Number of reports</p></td></tr><tr><td><p>Dabigatran</p></td><td><p>1,552</p></td></tr><tr><td><p>Rivaroxaban</p></td><td><p>3,291</p></td></tr><tr><td><p>Apixaban</p></td><td><p>900</p></td></tr></tbody></table><p> </p><p> </p><p>A full list of the type and number of reactions, broken down by the reaction term, is publically available for each medicine on the MHRA website. It is important to note that Yellow Card reports are not proof of a side effect occurring due to the medicine but only a suspicion by the reporter that the medicine may have caused the side effect. Yellow Card reports may therefore relate to true side effects of the medicine, or they may be due to coincidental illnesses that would have occurred in the absence of the medicine.</p><p> </p><p>Dabigatran, rivaroxaban and apixaban are anticoagulant medicines used to prevent or treat blood clots. The most commonly reported adverse reaction for all three medicines is gastrointestinal haemorrhage or bleeding, which is in keeping with the known anticoagulant effects of these medicines. Other relatively commonly reported suspected adverse reactions include bleeding at other sites of the body, gastrointestinal symptoms (such as nausea, pain and diarrhoea), anaemia, and rash. These adverse reactions are described in the product information, in both the Patient Information Leaflet for patients and the Summary of Healthcare Products for healthcare professionals.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/03/2016 11:16:20 answering member 4020 label Biography information for George Freeman
tabling member	545 label Biography information for Paul Flynn

416196

registered interest
date	04/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Commissioning Groups
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effectiveness of Clinical Commissioning Groups incentive schemes.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	8673
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>Incentive schemes for clinical commissioning group (CCGs) commissioning are primarily a matter for NHS England.</p><p> </p><p> </p><p> </p><p>NHS England’s Commissioning Committee reviewed the incentives for CCGs and providers in July 2015, and noted that “there is inconclusive evidence as to the consistent effectiveness of current incentives” .</p><p> </p><p> </p><p> </p><p>The Committee asked for futher work to be done and for proposals to simplify the incentive schemes to be brought back later in the year.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 15:40:27 answering member 4020 label Biography information for George Freeman
tabling member	545 label Biography information for Paul Flynn

416205

registered interest
date	04/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Productivity
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to implement the recommendations of the Interim Report of the Review of Operational Productivity in NHS Providers, published in June 2015.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	8694
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>Since the interim report on the review of operational productivity in NHS providers was published in June 2015, the Department has been working continuously with its arm’s length bodies to ensure delivery of the recommendations.</p><p> </p><p>Two tools in development are the “Adjusted Treatment Index” and the “Model Hospital”, both of which will be made available to the NHS for further development in order to help improve performance across the hospital sector. Additionally, several initiatives are under way including improvement collaboratives to support workforce efficiency programmes in nursing , hospital pharmacy and medicines optimisation, estates and facilities management and procurement.</p><p> </p><p>Lord Carter will complete his review with a full report, which is due later this year.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 16:35:20 answering member 4020 label Biography information for George Freeman
tabling member	545 label Biography information for Paul Flynn

346864

registered interest
date	27/05/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his Department's policies of recent Medicines and Healthcare Products Regulatory Agency guidelines on prescribing sodium valproate during pregnancy; and if he will implement stronger guidelines to minimise the risks of fetal valproate syndrome from use of sodium valproate.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	272
answer	answer is ministerial correction date of answer 05/06/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is responsible for developing national clinical guidelines to secure consistent, high quality, evidence based care for patients using the National Health Service. The NICE guideline on epilepsy, <em>The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care</em>, makes clear that to enable informed decisions and choice, women and girls with epilepsy must be given accurate information and counselling about contraception, conception and pregnancy.</p><p> </p><p> </p><p> </p><p>The Department worked with the Medicines and Healthcare products Regulatory Agency, healthcare professionals and patient groups to raise awareness and encourage discussion about the risks and benefits of sodium valproate between healthcare professionals and their patients. Several measures were put in place to minimize the prescribing of sodium valproate to women of childbearing potential (except where other drugs are ineffective or not tolerated) and to communicate the warnings around the drug sodium valproate to healthcare professionals and patients (particularly women of child bearing potential). These include:</p><p> </p><p>- working with the Health and Social Care Information Service on introducing red-flag warnings on general practitioners and community pharmacy IT systems;</p><p> </p><p>- updating the British National Formulary (BNF) and BNF for children (BNFc);</p><p> </p><p>- using existing Departmental and NHS communication channels to raise awareness and provide information to patients; and</p><p> </p><p>- working with the relevant Royal Colleges and professional bodies to communicate with their members and raise awareness.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/06/2015 11:51:37 answering member 4020 label Biography information for George Freeman
tabling member	545 label Biography information for Paul Flynn

224741

registered interest
date	03/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Transatlantic Trade and Investment Partnership
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the potential impact of the Transatlantic Trade and Investment Partnership (TTIP) on the NHS; and what conversations he has had with ministerial colleagues to discuss ways of ensuring that TTIP will not lead to further privisation of the NHS.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	226094
answer	answer is ministerial correction date of answer 10/03/2015 answer text <p>The Government is clear that the Transatlantic Trade and Investment Partnership (TTIP) will not affect the way the National Health Service takes decisions about who best should provide NHS services.</p><p> </p><p> </p><p> </p><p>This position has been confirmed by both the United States and European Union negotiators. Most recently, Cecilia Malmstrom, the European Commissioner for Trade, wrote to Lord Livingston at the Department for Business, Innovation and Skills (BIS) to confirm that:</p><p> </p><p> </p><p> </p><p>- Member States do not have to open public health services to competition from private providers, nor do they have to outsource services to private providers;</p><p> </p><p>- Member States are free to change their policies and bring outsourced services back into the public sector whenever they choose to do so, in a manner respecting property rights (which in any event are protected under UK law); and</p><p> </p><p>- It makes no difference whether a Member State already allows some services to be outsourced to private providers, or not.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The Department is working closely with colleagues at BIS as the negotiations on TTIP progress.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/03/2015 16:15:29 answering member 4020 label Biography information for George Freeman
tabling member	545 label Biography information for Paul Flynn